To investigate the basis of subclinical alveolitis in patients with primary biliary cirrhosis, 10 primary biliary cirrhosis patients were studied by bronchoalveolar lavage. Both bronchoalveolar lavage lymphoid and non-lymphoid cell populations were analysed using immunocytological methods to determine their proportions and phenotypic features in an attempt to gain information as to possible immune mechanisms active in the lung ofthese patients. Six of the 10 patients in our study showed evidence of an alveolitis (raised lymphocyte count: 27-6 (4.3)% of total count) on lavage. The results were compared with control groups of normal volunteers and patients with active pulmonary sarcoidosis. The six primary biliary cirrhosis patients with lymphocytosis had a raised CD4/CD8 T-cell ratio (4.13:1), similar to the sarcoid patients (5.60:1). A proportion of these T-lymphocytes expressed markers of activation (HLA-DR+ 7.5 (2.1)%); CD25+2-3 (09)%; (1.5)%. This increased T-cell activation was also seen in the sarcoid groups (HLA-DR+ 10.0 (1.9)%; CD25+3-0 (1.1)%; CD7+5*0 (02)%). This was not seen in the primary biliary cirrhosis patients without lymphocytosis and the normal volunteers. Within the non-lymphoid cell population, an increase in dendritic (RFD1+) celis was seen in primary biliary cirrhosis patients with lymphocytosis (31.2 (1-9)%) and sarcoid patients (46.3 (5
lymphocyte count: 27-6 (4.3)% of total count) on lavage. The results were compared with control groups of normal volunteers and patients with active pulmonary sarcoidosis. The six primary biliary cirrhosis patients with lymphocytosis had a raised CD4/CD8 T-cell ratio (4.13:1), similar to the sarcoid patients (5.60:1) . A proportion of these T-lymphocytes expressed markers of activation (HLA-DR+ 7.5 (2.1)%); CD25+2-3 (09)%; (1.5)%. This increased T-cell activation was also seen in the sarcoid groups (HLA-DR+ 10 .0 (1.9)%; CD25+3-0 (1.1)%; CD7+5*0 (02)%). This was not seen in the primary biliary cirrhosis patients without lymphocytosis and the normal volunteers. Within the non-lymphoid cell population, an increase in dendritic (RFD1+) celis was seen in primary biliary cirrhosis patients with lymphocytosis (31.2 (1-9)%) and sarcoid patients (46.3 (5.1)%) in contrast with the normal and primary biliary cirrhosis group without lymphocytosis. The primary biliary cirrhosis patients without lymphocytes had a relatively greater proportion of mature phagocytes (RFD7+). We postulate that these observations suggest the emergence in the lung of a granuloma producing mechanism similar to that occurring in the liver. By comparison, the alveolitis found in primary biliary cirrhosis is consistent with that observed in interstitial granulomatous lung disorders such as sarcoidosis.
Primary biliary cirrhosis is a chronic progressive liver disease. It is characterised by a granulomatous, destructive inflammation of intrahepatic bile ducts with eventual portal fibrosis and cirrhosis. ' The rate at which the disease progresses varies considerably, producing a wide clinical spectrum.I Raised serum bilirubin concentrations reflect a poor prognosis,3 while patients with focal granulomatous lesions in their livers have a better prognosis.4 Factors determining this disease progression are ill understood. A number of abnormalities of the immune system have been described in primary biliary cirrhosis,56 but whether these arise as a consequence of the liver disease or whether they are implicated in either the initiation or progression of the disease process remains unclear.
The true incidence of pulmonary complications in patients with primary biliary cirrhosis is unknown; however, the possible involvement of the lung during the course of primary biliary cirrhosis is acknowledged." Observations range from reports of associated fibrosing alveolitis8 to the presence of parenchymal granulomata mimicking pulmonary sarcoidosis. Figure: The above represents the percentage of morphologically identifiable lymphocytes in the bronchoalveolar lavage ofeach subject investigated. In comparison to the normal volunteers, lymphocyte proportions in bronchoalveolar lavage were significantly higher in both primary biliary cirrhosis patients (p<OOI) and sarcoid patients (p<0000I). (Table II) . A small proportion of Tlymphocytes expressed markers of activation being positive with RFDR1, CD7 and CD25.
McAbs both in PBC patients with evidence of lymphocytosis (7-5 (2-1)%, 5*8 (1-5)%, 2-3 (0 9)% respectively) and in the sarcoid groups (10 0 (1-9)%, 5.0 (0-2)%, 3 0 (1-1)% respectively). This was not seen in the other two groups (Table III) . Within the non-lymphoid cell population, an increase in proportion of RFD1 + cells was seen in primary biliary cirrhosis patients with lymphocytosis (31-2) (1 9)%) and sarcoid patients (46 3 (5 * 1)% in contrast with the normal (13-6 (2-1)% and the PBC group without lymphocytosis (6-5 (1 1 cells in any of the groups. In those primary biliary cirrhosis patients without lymphocytosis, a greater proportion of macrophages were RFD7+ (Table IV) .
RELATIONSHIP OF BRONCHOALVEOLAR LAVAGE DATA TO BIOLOGICAL AND HISTOLOGICAL STAGING
The normal range for serum bilirubin level in our study was taken as 5-17 mmol/l. Six of our patients with primary biliary cirrhosis had hyperbilirubinaemia, of whom only two showed a lymphocytosis in their lavage. All the remaining four patients with lymphocy tosis had normal serum bilirubin levels. (Table V) . Only one of our primary biliary cirrhosis patients had early disease on liver biopsy staging (stage 1); this patient had increased lymphocyte numbers in lavage. Four patients showed moderately advanced primary biliary cirrhosis (stage 2), three of whom had lymphocytosis. The remaining five primary biliary cirrhosis patients had late stage disease in their liver biopsies; only two of these patients had lymphocytosis (Table  V) .
Discussion
Our study has shown that a proportion of patients with primary biliary cirrhosis develop subclinical alveolitis. The alveolitis is charac- Primary biliary cirrhosis 312 (1-9)* 38 1( 5 7 Rodriguez-Roisin et al32 concluded that the observed lung disease in primary biliary cirrhosis patients was probably the result of associated Sjogren's syndrome; yet none of our primary biliary cirrhosis patients had any associated clinical disease. As no lung biopsies were performed in our study (patients were asymptomatic with clear CXR), it may seem that our data only reflect the existence of an inflammation in the lower respiratory tract, and therefore do not necessarily represent interstitial lung involvement. It is now accepted, however, that the initial lesion in granulomatous lung disorders is an alveolitis, which may proceed to granuloma formation within the parenchyma. ' 
